J

Johnson & Johnson

Makes prescription drugs and medical devices

Senior Automation Engineer - Drug Product, Aseptic Filling

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
No salary listed
Senior
Bachelor's
Wilson, NC, USA
In PersonFull-time on-site in Wilson, NC; frequent travel (>25%) during facility design, including domestic and international project travel.
Electrical EngineeringControls & Automation Engineering

About the job

Requirements
  • A minimum Bachelor's degree in Engineering, Computer Science, Science, or a related technical field is required.
  • At least 6 years of progressive automation and controls engineering experience in pharmaceutical or biopharmaceutical manufacturing is required.
  • Direct technical ownership of automated manufacturing systems in a current Good Manufacturing Practice (cGMP) environment, with hands-on responsibility for automation and controls scope supporting manufacturing operations and/or capital projects, is required.
  • Proven Drug Product automation experience supporting aseptic or sterile manufacturing, including automated filling, inspection, assembly, packaging, or related highly automated systems, is required.
  • Hands-on experience with ISA-95 Level 1 and Level 2 automation systems is required, including programmable logic controller (PLC) and/or distributed control system (DCS) controls, supervisory control and data acquisition (SCADA)/human-machine interface (HMI), batch or sequence control, machine controls, industrial networks, communication protocols, operational technology (OT) infrastructure, and associated hardware and interfaces.
  • Experience developing, reviewing, implementing, and troubleshooting automation software, system configurations, and engineering deliverables is required, including functional and design specifications, control narratives, interface definitions, alarm and interlock requirements, and system architectures.
  • Proven automation project execution experience is required, including original equipment manufacturer (OEM) and system integrator coordination, controls design reviews, factory acceptance testing (FAT)/site acceptance testing (SAT), commissioning, qualification, start-up support, troubleshooting, and automation change control.
  • A solid understanding of ISA-88 and ISA-95 standards and their application within regulated manufacturing environments is required.
  • Knowledge of cGMP and computerized system validation expectations is required, including GAMP 5, 21 CFR Part 11, EU GMP Annex 11, data integrity, and risk-based validation principles.
  • Experience integrating manufacturing automation with Level 3 systems such as manufacturing execution systems (MES), historian, recipe management, data platforms, and related business or quality systems is required.
  • Strong written and verbal communication skills are required, including the ability to partner across Automation, Manufacturing, Process Engineering, Quality, Computerized System Validation (CSV), OT Infrastructure, Digital, OEM, system integrator, and project teams while maintaining clear ownership of automation and controls deliverables.
  • Ability and willingness to support project travel and on-site execution needs, including periodic international travel to supplier/OEM, system integrator, and company affiliate sites for training, FAT, automation testing, and related project activities, is required.
  • Candidates whose experience is limited to process engineering, validation, manufacturing operations, or equipment engineering without direct hands-on automation and controls responsibility will not meet the requirement.
Responsibilities
  • Serve as the area Automation Engineer for Drug Product aseptic filling and provide direct technical ownership of the automation and controls scope under the Drug Product Manufacturing Lead.
  • Support end-to-end automation delivery from concept and detailed design through controls development, FAT/SAT, construction support, commissioning, qualification, start-up, handover, troubleshooting, and steady-state lifecycle support.
  • Provide technical oversight for automation solutions supporting aseptic filling/finish operations and associated highly automated Drug Product equipment, including applicable isolator or barrier technologies, machine controls, batch/sequence control, SCADA/HMI, industrial networks, robotics, and site-system interfaces.
  • Review and challenge OEM and system-integrator automation designs, software/configuration, functional and design specifications, control narratives, system architectures, interface definitions, alarms/interlocks, and test documentation to ensure alignment with site and global automation standards.
  • Develop, implement, review, and troubleshoot PLC/DCS/HMI/batch and machine-control changes within the assigned area; ensure software and configuration are maintainable, standardized, documented, and appropriately controlled.
  • Plan, support, and execute automation FAT/SAT, commissioning, qualification, and start-up activities; lead technical issue resolution and drive automation punch-list items to closure.
  • Travel domestically and internationally, as required, to supplier/OEM, system-integrator, and company affiliate sites for FAT, technical training, knowledge transfer, and automation readiness.
  • Support automation interfaces to MES, historian, recipe/data platforms, and other site systems; ensure reliable data flow, traceability, and system integration for Drug Product manufacturing operations.
  • Author, review, and execute automation-related validation and qualification documentation; support risk assessments, investigations, deviations, corrective and preventive actions (CAPA), change controls, and regulatory/internal inspections.
  • Apply sound automation engineering principles, cGMP requirements, GAMP 5 practices, data-integrity expectations, cybersecurity controls, and lifecycle-management standards throughout the system lifecycle.
  • Partner with Manufacturing and Process Engineering on process requirements while retaining technical ownership of the automation/controls solution. Translate approved process and equipment requirements into robust, testable automation functionality.
  • Coordinate technically with equipment vendors, OEM controls teams, system integrators, CSV, OT Infrastructure, MES, Digital, Quality, and other partners to deliver an integrated and supportable solution.
  • Support operational readiness through training, documentation, maintenance/support models, spare-parts considerations, disaster-recovery/business-continuity planning, and transfer of automation-system knowledge to the site organization.
  • Use automation performance data and operational experience to identify continuous-improvement opportunities in reliability, system performance, validation efficiency, and manufacturing support.
  • Provide full-time on-site support in Wilson, North Carolina; support facility design at an engineering firm with frequent travel (>25%) until the project shifts to the Wilson plant site.
Desired Qualifications
  • Direct automation engineering experience with aseptic filling/finish equipment and associated isolator or restricted-access barrier technologies.
  • Experience with batch/sequence control, machine controls, robotics, motion control, and integration of aseptic filling equipment with MES and historian platforms.
  • Experience delivering automation scope for a large pharmaceutical capital project from design through controls development, FAT/SAT, commissioning, qualification, start-up, and operational handover.
  • Hands-on experience with platforms such as Rockwell Automation, Siemens, Emerson DeltaV, OSI PI, Werum PAS-X, or comparable PLC, DCS, SCADA/HMI, historian, and MES technologies.
  • Experience with reliability engineering, automation lifecycle management, operational readiness, and maintenance/support strategy development.
  • A good understanding of Industry 4.0, Industrial Internet of Things, advanced analytics, and evolving digital capabilities used to transform biopharmaceutical manufacturing.
  • Experience working with multiple OEMs, engineering partners, automation vendors, and system integrators in a global or multi-site organization.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.